Research in Experimental Medicine

, Volume 193, Issue 1, pp 97–103 | Cite as

Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7–36) amide on the rat pancreas

  • Rüdiger Göke
  • Birte Wagner
  • Hans-Christoph Fehmann
  • Burkhard Göke
Original Papers


The glucose-dependent action of GLP-1 (7–36) amide (GLP-1) on insulin secretion was studied in isolated islets and in the perfused rat pancreas. In islet experiments in the presence of non-stimulatory glucose levels (<3 mmol/1) a GLP-1 concentration of 10 nmol/1 increased insulin secretion by 83%. However, higher GLP-1 concentrations (25 and 100 nmol/l) could not further enhance this effect (85 and 83%, respectively). The onset of the stimulatory action of a supramaximal GLP-1-load (25 nmol/l) was at a glucose level of 3 mmol/l. In the perfused pancreas, 25 nmol/l GLP-1 induced a strong insulin release at 5 mmol/l glucose, but under basal glucose (2.8 mmol/l) only a slight enhancement of insulin secretion occurred during the late phase (30 to 54 min) of perfusion (P<0.05). In conclusion, a slight but not dose-dependent stimulation of insulin secretion by supramaximal GLP-1 loads under basal glucose levels was found. The necessary GLP-1 concentrations to achieve this in vitro effect are beyond physiological or postprandial levels.

Key words

Glucagon-like peptide-1 Islets Perfused pancreas Insulin secretion Glucose dependency 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bailey, CJ, Flatt PR (1987) Glucagon-like peptide 1 and the entero-insulinar axis in obese hyperglycemic mice. Life Sci 40:521–525PubMedCrossRefGoogle Scholar
  2. 2.
    Creutzfeldt W (1980) Insulinotropic factors of the gut—the broadening incretin concept. Gastroenterology 78:1631–1632.PubMedGoogle Scholar
  3. 3.
    Creutzfeldt W, Ebert R (1985) New developments in the incretin concept. Diabetologia 28:565–573PubMedCrossRefGoogle Scholar
  4. 4.
    Ebert R (1990) Gut signals for islet hormone release. Eur J Clin Invest 20 (S1): 20–26Google Scholar
  5. 5.
    Elliott R, Morgan L, Tredger, J, Charles S, Wright J, Marks V (1991) The effects of carbohydrate, fat and protein on glucagon-like peptide-1 secretion in man (abstract). J Endocrinol 131 [Suppl] 62Google Scholar
  6. 6.
    Fehmann HC, Göke R, Göke B (1992) Glucagon-like peptide 1 (7–37)/(7–36) amide is a new incretin hormone. Mol Cell Endocrinol 85: C39-C44PubMedCrossRefGoogle Scholar
  7. 7.
    Fridolf T, Böttcher G, Sundler F, Ahren B (1991) GLP-1 and GLP-1 (7–36) amide: Influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 6: 208–215PubMedCrossRefGoogle Scholar
  8. 8.
    Göke, B, Elsebach K, Hausmann W, Schaar M, Arnold R, Adler G (1987) Endocrine pancreatic morphology and function in exocrine insufficiency in rats. Am J Physiol 253:G139–145PubMedGoogle Scholar
  9. 9.
    Göke, R, Fehmann HC, Göke B (1991) Glucagon-like peptide 1 (7–36) amide is a new incretin enterogastrone candidate. Eur J Clin Invest 21: 135–144PubMedCrossRefGoogle Scholar
  10. 10.
    Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y, Yamashita K (1989) Comparison of the effects of glucagon-like peptide 1 (1–37) and −(7–37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 124: 1768–1773PubMedCrossRefGoogle Scholar
  11. 11.
    Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S (1989) Glucagonostatic and insulinotropic actin of glucagonlike peptide 1(7–36) amide. Diabetes 38:902–905PubMedCrossRefGoogle Scholar
  12. 12.
    Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide 1(7–36): a physiological incretin in man. Lancet II:1300–1304CrossRefGoogle Scholar
  13. 13.
    Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39PubMedGoogle Scholar
  14. 14.
    McIntyre N, Holdsworth CD, Turner DS (1964) New interpretation of oral glucose tolerance. Lancet II: 20–21CrossRefGoogle Scholar
  15. 15.
    Miholic J, Orskov C, Holst JJ, Kotzerke J, Meyer HJ (1991) Emptying of the the gastric substitute, glucagon-like peptide 1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36: 1361–1370PubMedCrossRefGoogle Scholar
  16. 16.
    Orskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of non-insulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415–423PubMedGoogle Scholar
  17. 17.
    Shima K, Hirota M, Ohboshi C (1988) Effect of glucagon-like peptide-1 on insulin secretion. Regul Peptides 22: 245–252CrossRefGoogle Scholar
  18. 18.
    Siegel EG, Creutzfeldt W (1988) Hormone responsiveness of collagenase-isolated rat islets is markedly increased by short-term maintenance in tissue culture. Horm Metab Res 20: 184–185PubMedCrossRefGoogle Scholar
  19. 19.
    Weir GC, Mojsov S, Hendrick GK, Habener JF (1989) Glucagonlike peptide 1 (7–37) actions on endocrine pancreas. Diabetes 38: 338–342PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Rüdiger Göke
    • 1
  • Birte Wagner
    • 1
  • Hans-Christoph Fehmann
    • 1
  • Burkhard Göke
    • 1
  1. 1.Laboratory of Molecular Endocrinology, Division of Gastroenterology, Department of Internal MedicinePhilipps University of MarburgMarburgGermany

Personalised recommendations